Kestra Private Wealth Services LLC Has $1.40 Million Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Kestra Private Wealth Services LLC increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 4,140 shares of the medical equipment provider’s stock after purchasing an additional 373 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Intuitive Surgical were worth $1,397,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. WCM Investment Management LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $575,536,000. International Assets Investment Management LLC raised its holdings in shares of Intuitive Surgical by 32,360.5% in the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after purchasing an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd raised its holdings in shares of Intuitive Surgical by 113.2% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after purchasing an additional 677,455 shares during the period. J.P. Morgan Private Wealth Advisors LLC bought a new stake in shares of Intuitive Surgical in the 3rd quarter valued at about $178,667,000. Finally, Quadrature Capital Ltd raised its holdings in shares of Intuitive Surgical by 466.2% in the 3rd quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock valued at $99,601,000 after purchasing an additional 280,480 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $375.39, for a total transaction of $141,146.64. Following the completion of the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at $2,067,272.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $375.39, for a total transaction of $141,146.64. Following the completion of the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at $2,067,272.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 226,928 shares of company stock valued at $87,833,828. Insiders own 0.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird dropped their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a report on Friday, April 19th. Stifel Nicolaus increased their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. Jefferies Financial Group increased their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Barclays increased their price target on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Finally, StockNews.com cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $381.36 on Friday. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The firm has a market capitalization of $135.27 billion, a P/E ratio of 68.84, a P/E/G ratio of 4.88 and a beta of 1.39. The company’s 50 day moving average price is $385.56 and its two-hundred day moving average price is $348.56.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same quarter last year, the business posted $1.00 earnings per share. The company’s quarterly revenue was up 11.5% on a year-over-year basis. On average, analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.